Point72 Asset Management
TRIL

Point72 Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Point72 Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-473,600
Closed -$6.97M – 1284
2020
Q4 		$6.97M Buy
+473,600
New +$6.83M 0.03% 525
2020
Q3 		– Sell
-187,191
Closed -$1.51M – 1163
2020
Q2 		$1.51M Sell
187,191
-845,903
-82% -$5.23M 0.01% 634
2020
Q1 		$4.17M Buy
+1,033,094
New +$3.91M 0.03% 405
2016
Q4 		– Sell
-369,300
Closed -$5.46M – 888
2016
Q3 		$5.46M Hold
369,300
– – 0.04% 401
2016
Q2 		$3.32M Buy
369,300
+29,300
+9% +$304K 0.02% 497
2016
Q1 		$3.15M Buy
340,000
+141,400
+71% +$1.19M 0.02% 506
2015
Q4 		$2.5M Hold
198,600
– – 0.02% 520
2015
Q3 		$2.59M Buy
198,600
+10,437
+6% +$192K 0.02% 528
2015
Q2 		$4.11M Buy
+188,163
New +$4.29M 0.03% 478

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Point72 Asset Management's TRIL Position: Q1 2021 in Review

Point72 Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2021, closing a stake of 473,600 shares — an estimated $6.97M sold.

Point72 Asset Management first reported a position in TRIL in Q2 2015 and held it in 9 quarters. The position peaked at $6.97M in Q4 2020. 125 funds tracked by Wall St. Rank hold TRIL as of Q1 2021.

  • Point72 Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q1 2021 after selling out during the quarter.
  • Point72 Asset Management sold 473,600 Trillium Therapeutics Inc. shares in Q1 2021, an estimated $6.97M.
  • Point72 Asset Management first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 9 quarters.
  • Point72 Asset Management's Trillium Therapeutics Inc. position peaked at $6.97M in Q4 2020.
  • 125 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2021.

Based on Point72 Asset Management's 13F filing for Q1 2021, filed 17 May 2021.